The safe and efficient use of herpes simplex virus (HSV)-viruses paradoxically deliver genes at much higher based vectors to deliver genes of potentially therapeutic efficiency than the less disabled single mutant lacking benefit to the central nervous system will require their ICP34.5 alone and also, as expected, produce less dameffective disablement by the inactivation of viral genes age in vivo. Moreover, unlike the single mutant lacking required for lytic growth. Here we report that viruses lack-ICP27 the double mutant viruses cannot revert to wild-type ing functional genes for ICP27 (which is required for growth by acquistion of complimenting gene sequences during in all cell types) and ICP34.5 (which is required for growth growth of virus stocks in vitro on dividing cells expressing in nondividing cell types) can deliver a marker gene to both ICP27 since artificial expression of ICP34.5 in these cells
Introduction
Herpes simplex virus (HSV) has a number of advantages which make it a potentially useful vector for gene delivery to the nervous system (for reviews see . The virus has a large genome size of approximately 150 kb and contains a number of nonessential genes, thereby providing the possibility of inserting foreign genes which are much larger than those that can be accommodated in other viral vectors such as adenovirus or retroviruses which have a much smaller genome size. Moreover, the virus naturally establishes life-long asymptomatic infections of the nervous system. [4] [5] [6] In latent infections of neuronal cells, the viral gene expression characteristic of lytic infections is specifically silenced whilst one region of the virus genome encoding the latency-associated transcripts (LATs) remains transcriptionally active throughout latent infection. 7 Hence the possibility exists of inserting a foreign gene into the virus genome and establishing a nondamaging latent infection in which the foreign gene would continue to be expressed in the long term.
In order to achieve this however, it is necessary to effectively disable the virus so that it can no longer pro-duce a damaging lytic infection. Thus injection of wildtype virus into the brain of normal or immunodeficient mice will result in lytic infection leading to a lethal encephalitis with an LD 50 of Ͻ10 2 p.f.u. 8 Two approaches have been taken to overcome this problem. These involve either the deletion of genes essential for lytic infection from the virus so that it can no longer replicate lytically (see for example Ref. 9) or the use of amplicon vectors containing a herpes virus origin of replication and DNA packaging signal but lacking other virus sequences (see for example Ref. 10) . Such amplicon vectors require a helper herpes virus for their propagation which must evidently be disabled in a similar manner to recombinant viruses carrying a foreign gene, if damaging lytic infection is not to occur when the amplicon and the helper virus used in its propagation are injected into the brain.
Both approaches therefore require the effective disablement of HSV by the removal of genes required for damaging lytic infections. Initial approaches in this area concentrated on the removal of one or more of the viral immediate-early genes such as ICP4 which are essential for lytic infection in all cell types. These approaches suffer however from the difficulty that stocks of these disabled viruses need to be grown on cell lines which have been artificially engineered to express the deleted immediate-early gene and thereby complement the defect in the virus. As the initial cell lines of this type were prepared for studies of viral gene regulation, their viral sequences overlap sequences contained in the deleted virus vector, thereby opening the possibility of homologous recombination regenerating wild-type virus. Indeed in a recent experiment using an ICP4-deleted helper virus, the expression of tyrosine hydroxylase in an amplicon vector was able to revert the symptoms in the 6-hydroxydopamine rodent model of Parkinson's disease but 10% of the injected animals died due to the replication of wild-type virus presumably generated by recombination.
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As an alternative approach to disabling the virus, it is also possible to inactivate genes which are required for neurovirulence and replication in the brain. This would theoretically allow the virus to be grown in culture on nonengineered dividing cells but to be safe for injection into the brain. Although a number of viral genes are necessary for neurovirulence the deletion of some of these such as those encoding ICP6 or thymidine kinase does not provide an absolute block to replication in the brain and they are thus not suitable for production of viral vectors. 12, 13 However, the ICP34.5 protein has been shown to be absolutely required for a neurovirulent phenotype. Thus ICP34.5 deletion mutants have an LD 50 of Ͼ10 6 p.f.u. following intracerebral inoculation into mice. 8, 14 Despite this however, mutants lacking functional ICP34.5 can replicate in vitro in dividing cells and can also establish latency in vivo. 15, 16 They thus represent an excellent candidate for gene therapy vectors with no requirement for growth in a complimenting cell line and hence no possibility of reversion to a neurovirulent phenotype.
We have previously reported that ICP34.5− mutants of HSV-1 can deliver a marker ␤-galactosidase gene to both the central and peripheral nervous systems in vivo 17 as well as to cardiac myocytes. 18 Hence mutants lacking functional ICP34.5 could be used as a basis for the development of safe and effective gene therapy vectors. Clearly however, such vectors still retain the possibility of replicating in dividing cells both in the brain and particularly elsewhere. It is therefore necessary to disable such vectors further before their use for human gene therapy could be contemplated. Here we report the further disablement of such ICP34.5− viruses by inactivating the gene encoding the immediate-early protein ICP27 an immediate-early protein which is required for virus growth in all cell types. 19 Stocks of these viruses are grown on a newly prepared cell line which contains a functional ICP27 gene lacking any DNA sequences in common with those present in the mutant viruses thereby preventing any possibility of homologous recombination generating wild-type virus. Interestingly, an ICP27−, ICP34.5− double mutant virus not only produces far less damage on inoculation into the CNS than an ICP34.5− virus but also delivers a marker gene to approximately 500-fold more neuronal cells when injected at a similar titre. Hence ICP27−, ICP34.5− double mutant viruses offer a basis for the development of efficient gene therapy vectors which are likely to be ultimately safe enough for use in human individuals.
Results
As an additional safety measure in creating ICP27− viruses, we inactivated the ICP27 gene by inserting the marker ␤-galactosidase gene into the ICP27 locus ( Figure 1 ). This has the safety advantage that if any recombination were to occur between the recombinant virus and a wild-type virus it would be impossible to generate a replication-competent recombinant virus carrying both the ␤-galactosidase gene and a functional ICP27 gene. Accordingly, a ␤-galactosidase gene under the control of the Moloney murine leukaemia virus (MMLV) LTR promoter was inserted into the ICP27 region of the herpes genome within a plasmid vector. As illustrated in Figure 1 this insertion removes the entire ICP27 gene, as well as the adjacent UL55 gene and a part of the UL56 gene. The promoter/reporter construct flanked by herpes virus sequences was then introduced into the ICP27 gene of the HSV-1 mutant 1716 which is derived from HSV1 strain 17+ but lacks the gene for ICP34.5. 8 In addition, for comparison, we also introduced this construct into the ICP27 locus of wild-type HSV1 strain 17+. Recombinant viruses were selected on the basis of their ability to grow on BHK-21 cells 20 which had been artificially engineered to express the ICP27 gene, whilst being unable to grow on unmodified BHK-21 cells whereas all the parental viruses were able to grow on both unmodified and modified cells.
The BHK-21 cells used in the isolation and propagation of the ICP27− viruses were prepared by stably transfecting parental BHK-21 cells with a plasmid containing the ICP27 gene. The fragment of the herpes genome containing the ICP27 gene used in these experiments consists entirely of sequences deleted from the virus vector during the preparation of ICP27− viruses so that no homologous recombination can occur during the propagation of the ICP27− viruses. In order to confirm that the ICP27− viruses could be successfully propagated without any reversion to wild type of virus, plaque-purified isolates of each virus were grown on the modified BHK cells expressing ICP27 and supernatants subsequently plated on to unmodified BHK cells. In these experiments up to 10 9 p.f.u. of mutant virus (the maximal amount tested) could be plated on to modified cells in this manner without any virus capable of growing in the absence of ICP27 being detectable upon plating on to BHK cells. Hence these viruses have reversion frequencies to wild type of less that 10 −9 . Having established that ICP27− viruses did not revert to wild type, we investigated their effect on the sodium current of dorsal root ganglion (DRG) neurons following infection in vitro. This is of importance since the neuron's fundamental role is signaling and voltage-gated sodium channels are responsible for the generation and propagation of action potentials, the electrical signals. Activation of sodium channels mediates a rapid increase in sodium ion permeability which causes depolarization in the initial phase of the action potential. It is known that by 24 h after infection with wild-type HSV-1 most (70%) of DRG neurons have entirely lost the sodium current and hence their excitability and this loss affects both the tetrodotoxin-sensitive (TTXs) and tetrodotoxin-resistant (TTXr) sodium currents which have different characteristics (Ref. 6 and Storey et al, submitted). It is therefore important that viral vectors delivering genes to neurons do not compromise neurological function in this manner.
Accordingly, each of the viruses expressing ␤-galactosidase was used to infect cultured DRG neurons using a multiplicity of infection sufficient to infect Ͼ95% of cells in culture (5 p.f.u. per cell). Twenty-four hours after infection TTXs and TTXr currents were measured and com- pared to those in uninfected neurons or those infected with wild-type HSV-1. TTXs and TTXr currents were separated on the basis of their inactivation properties. The total sodium current was evoked by a depolarisation step to −20 mV after a prepulse of −120 mV which removes the inactivation from all sodium channels. The TTXr sodium current was evoked by a step depolarization to −20 mV after a prepulse of −50 mV which removes inactivation from TTXr sodium channels. The TTXs sodium current was obtained by subtraction.
In these experiments ( Figure 2 ) the wild-type virus produced an almost total abolition of both the TTXr and TTXs sodium currents in accordance with our previous results (Storey et al, submitted). In contrast, none of the viruses containing mutations in ICP34.5 and/or ICP27 had any significant inhibitory effect on either of the sodium currents compared to that observed in uninfected cells. Hence the deletion mutants do not cause the severe decrease in the neuronal sodium current which is observed in infections with wild-type HSV-1. Moreover, while at 24 h cells infected with wild-type virus showed some level of toxic effects (cells rounded, neurites not produced), those infected with viruses deleted for ICP34.5 and/or ICP27 were phase bright and showed no signs of toxicity associated with virus infection.
In more detailed experiments with the mutant viruses,
Figure 2 Normalised tetrodotoxin resistant (TTXr) and tetrodotoxin sensitive (TTXs) sodium currents in uninfected DRG neurons (control) or neurons infected with wild-type HSV-1 or the mutant viruses 1716 (lacking functional ICP34.5), Z⌬MN16 (lacking functional ICP34.5 and ICP27) and Z⌬MN+ (lacking functional ICP27). The currents evoked were normalised for size of the cell by dividing by capacitance (nA/pF). Values are the average of the indicated numbers of measurements whose standard error is indicated by the bars. Note that only the wild-type virus is capable of significantly reducing the TTXr and TTXs currents. (Tukey's post hoc analysis P Ͻ 0.05).
a family of sodium currents was evoked from a holding potential of −80 mV after a prepulse to −120 mV (to remove sodium current inactivation) with 5 mV step depolarisations from −50 mV to +25 mV. The family of currents were normalised with respect to the peak current and averaged by the indicated number of cells tested. The normalised peak currents were plotted against the command potential giving the characteristic sodium current-voltage relationship. As illustrated in Figure 3 the current-voltage relationships of the uninfected neurons and those infected with each of the mutant viruses are superimposable and clearly show that infection with the mutant viruses has not altered the voltage dependence of the sodium currents. However, it should be stated that effects in DRGs may not necessarily reflect effects on other neuronal populations such as those in the CNS, but the results do indicate that deletion of ICP34.5 and/or ICP27 is at the very least likely to reduce considerably the effects on neuronal electrophysiology which are otherwise shown by wild-type HSV.
Having shown that none of our virus vectors produced the compromising effect on neurological function observed with wild-type virus, the viruses lacking functional ICP27 were then injected intra-cerebrally into rats and the efficiency of gene delivery compared to that observed with strain 1716 containing a functional ICP27 gene, by staining brain sections with the chromogenic substrate X-gal at intervals after inoculation ( Figure 4 , Table 1 ). Interestingly, inactivation of the ICP27 gene in a virus lacking functional ICP34.5 resulted in greatly enhanced gene delivery. Thus, for example, the Z⌬MN16 virus lacking both ICP27 and ICP34.5 gave a several hundred-fold higher number of neurons staining for ␤-galactosidase than the corresponding 1716 virus containing functional ICP27 at 2 days after inoculation.
A similar very high efficiency of gene delivery was observed with the Z⌬MN+ virus containing inactive ICP27 but functional ICP34.5, although in this case comparison with the corresponding virus containing functional ICP27 was not performed since such a wild-type virus would replicate lytically in the brain. Statistical analysis comparing the efficiencies Z⌬MN16 with The sodium current family generated were normalised with respect to the peak current. Note that all the mutant viruses have no effect on the voltage-current relationship which is normally observed.
Z⌬MN+ have not been performed due to insufficiencies in the sample size at each time-point. Hence ICP27− viruses appear to be able to produce much higher efficiencies of gene delivery than the corresponding virus containing functional ICP27. Indeed, the high efficiency of gene delivery of the ICP27− viruses resulted in these viruses producing detectable stained cells up to 10 days after inoculation (data not shown), although the number of these cells was very much lower than that observed at earlier time-points of infection in accordance with the previously reported relatively rapid inactivation of the MMLV promoter as the virus enters latency. 21 These experiments suggest therefore that viruses lacking ICP27 can deliver genes with high efficiency to the nervous system in vivo. We next wished to determine whether such gene delivery is accompanied by damage to the nervous system. The damage to the host tissue produced by the injection of the different mutants into the motor cortex was therefore examined both in the light microscope using toluidine blue-stained semithin sections and at the electron microscope level. The sections were cut horizontal to the cortex surface through the whole thickness of the cortex to enable the extent of any damage around the injection tract to be assessed. Control injections of diluent did not show any obvious damage to the host tissue in semi-thin sections although a few perivascular macrophages contained debris.
Three days after injection with all three viruses tested there was a large accumulation of macrophages and smaller numbers of lymphocytes and neutrophils within the host tissue around the injection site ( Figures 5 and 6 ). Many vacuoles were present within the neuropil, indicating the presence of dead and dying cells. Further from the injection site, perivascular cuffing of macrophages was seen. Although the pattern of macrophage infiltration and cell death at the centre of the injection site was similar with the three viruses, the injection of the 1716 virus into the motor cortex produced a much wider area containing infiltrating macrophages and more extensive loss of neuropil (panel e in Figures 5 and 6 ) than injection of Z⌬MN:+ (panel a) or Z⌬MN:16 (panel c).
Hence at 3 days after injection the 1716 virus clearly produces more extensive damage compared with that observed with either of the viruses containing a mutation in ICP27. At 1 week survival, the pattern of damage, macrophage infiltration and perivascular cuffing of macrophages was very similar to that seen at 3 days survival (data not shown).
However, by 2 weeks survival, the large area of macrophage infiltration produced by injection of the different viruses was no longer seen although there was still some perivascular macrophage cuffing. At the injection site there was a central core of tissue lost that was filled with macrophages. Surrounding this core of macrophages was a halo of tissue which contained very few neuronal or glial cell bodies. At 28 days after injection (Figures 5 and  6 ), by which time with the MMLV LTR promoter used there is no ␤-galactosidase expression, there was little sign of tissue damage with any of the viruses except for a compact central core of macrophages containing debris ( Figures 5 and 6 panels b, d and f) . This was surrounded by apparently normal neuropil although few neuronal perikaiya remained within 10-15 m of the core. Presumably the damaged tissue had been removed.
It is clear therefore that the damage produced by all Values indicate the number of X-gal-stained cells in a representative 75 m section of brain taken 2 days after infection and averaged from three independently inoculated animals.
three viruses is relatively minimal at periods of 2 weeks or more survival whilst at periods less than this there is a clear difference between the viruses with the Z⌬MN and Z⌬MN16 viruses lacking functional ICP27 producing considerably less damage than the 1716 virus strain. Hence, as expected, the deletion of ICP27 from an ICP34.5− virus results in an increase in its safety with reduced damage to neuronal cells in vivo, as well as the very unexpected dramatic increase in gene delivery efficiency as the virus is made more disabled. This indicates therefore that the ICP27−, ICP34.5− virus and the ICP27− virus both deliver a reporter gene with higher efficiency than the single ICP34.5− mutant and also produce less damage to the brain. The deletion of ICP27 thus produces a high efficiency vector whilst the further removal of ICP34.5 means that reversion to wild type during growth on ICP27 expressing cells in vitro would require not only recombination with the wild-type ICP27 gene (which occurs at a frequency of less than 10 −9 : see above) but also a random mutation in the ICP34.5 gene restoring its functional activity. It is therefore possible in this manner to produce a relatively safe vector without compromising gene delivery efficiency as is the case in a single mutant lacking only ICP34.5.
Although rodents offer a good test system for examining the effects of viral vectors in vitro, the ultimate development of herpes vectors for in vivo therapeutic use will require their testing in primate systems. Thus primates are not only more closely related to humans but also offer highly relevant models of human diseases such as the MPTP common marmoset model of Parkinson's disease. 22 We therefore carried out stereotactic injections of our ICP27-virus vectors into the brain of normal marmosets using similar amounts of ICP27-deleted virus as for the rat experiments, but here injecting into the striatum rather than the motor cortex. As illustrated in Figure 7 , significant numbers of ␤-galactosidase-positive cells were observed 2 days after injection indicating that our viruses were able to deliver a marker gene effectively to the primate brain. To our knowledge this is the first report of 
) stained with toluidine blue of rat motor cortex after injection with herpes virus vectors at 3 and 28 days after injection. Z⌬MN:+ at 3 days (a) and 28 days (b); Z⌬MN:16 at 3 days (c) and 28 days (d); 1716 at 3 days (e) and 28 days (f). At 3 days survival all three viruses show large numbers of infiltrating haematogenous cells (dark cells in the Figure) within the host tissue around the injection site and some loss of neurons. The section derived from rats injected with 1716 (e) shows the greatest area of tissue damage at 3 days. Neuronal nuclei (arrows) are only identifiable in the extremity of the field in panel e but are observed much closer to the centre of the injection site in panels a and c. In each case, by 28 days survival the numbers of haematogenous cells were greatly reduced leaving a central core of damage-containing macrophages (between arrow heads). Scale bar equals 10 m.
gene delivery to the normal primate brain with an HSVbased vector, although delivery to an intra-cranial glial tumour using HSV has previously been reported. 23 
Discussion
HSV-based vectors have been shown in a number of studies to be capable of expressing either a marker gene 9, 17, 21 or a gene of potential therapeutic benefit.
11,24-28
Thus, for example, the expression of nerve growth factor using such a vector was shown to prevent the cell death which normally occurs in sympathetic ganglia following axotomy. 24 Similarly the expression of tyrosine hydroxylase in this manner can relieve the abnormal rotational behaviour observed in the 6-hydroxidopamine rodent model of Parkinson's disease.
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Thus HSV-based vectors clearly have potential for the therapeutic delivery of specific genes to cells within the nervous system. However, these experiments were conducted with mutant viruses lacking a functional gene encoding the viral immediate-early protein ICP4, either within the recombinant virus itself or as a helper virus for an amplicon vector system. In all cases, stocks of the virus for injection were grown on engineered cell lines artificially expressing ICP4 in order to compliment the defect in the virus and allow the lytic replication required for viral growth. However, since such cell lines had been primarily prepared for studies of viral gene regulation using mutant viruses, the ICP4 gene in the cell lines contains significant regions of overlap with regions flanking ICP4 which remain in the mutant virus genome, thereby opening up the possibility of homologous recombination leading to the regeneration of wild-type virus. Similarly, although the expression of virus genes in mutants lacking ICP4 is limited to the immediate-early genes 29 considerable cytopathic effect is still observed with mutant viruses lacking ICP4 presumably due to the expression of the other immediate-early genes or to the presence of virion components which enter with the viral particle. 30 We have therefore explored the use of mutant viruses lacking the other essential immediate-early gene, that encoding ICP27. 19 Interestingly the use of ICP27− viruses has not previously been reported for gene delivery to the nervous system in vivo, although such viruses have been used to deliver genes to neuronal cells in vitro either as a recombinant virus 31 or as a helper virus for amplicon type vectors. 32 In the experiments reported here we have shown that all the mutant viruses we tested did not alter the amplitude or kinetic properties of either the TTXs or TTXr sodium currents in DRG neurons, although these currents are severely inhibited by wild-type virus. Hence these viruses do not compromise neurological function as the wild-type virus does.
Moreover, a single mutant virus lacking a functional gene encoding ICP27 can effectively deliver a marker ␤-galactosidase gene to neuronal cells in the CNS in vivo with high efficiency. This effect can be observed in both rodents and primates. Hence such ICP27− viruses have
Figure 6 Electron micrographs of rat motor cortex after injection with herpes virus vectors at 3 and 28 days after injections. Z⌬MN:+ at 3 days (a) and 28 days (b); Z⌬MN:16 at 3 days (c) and 28 days (d); 1716 at 3 days (e) and 28 days (f). At 3 days macrophages (M) surrounded by cellular debris are present near the centre of the injection site in all three cases, but in panel e no surviving neuronal cells or their axons/dendrites are observed, whereas these are still observed in panels a and c. After 28 days with each virus, the damaged tissue has been removed leaving a narrow core of macrophages (M) containing debris surrounded by comparatively normal neurophil. There is no indication of continuing cell death. b, blood vessels.
Scale bar = 2 m.
potential for development as gene therapy vectors. This is particularly true where, as in our case, the use of such viruses is combined with the use of a cell line engineered to express ICP27, but having no DNA overlap with sequences remaining in the mutant viruses. Hence such viruses can be grown in vitro on the ICP27 expressing cell line without the risk of homologous recombination regenerating a wild-type virus expressing functional ICP27, although it is still possible that this could occur by nonhomologous recombination.
Although no wild-type virus was generated from the ICP27− virus in our in vitro experiments we did observe some damage to the nervous system upon injection of the viruses presumably due to the expression of potentially cytopathic viral gene products which still occurs in such viruses despite their inability to replicate lytically. Hence it will be necessary to disable these viruses further before their use in human gene therapy procedures could be contemplated. Such disablement could involve, for example, the additional deletion of the gene encoding ICP4 with growth of the virus in vitro on cells expressing both ICP4 and ICP27.
Interestingly we have shown that the further disablement of such an ICP27− virus by removing functional ICP34.5 does not compromise the efficiency of gene delivery by the double mutant virus which is similar to that of the single mutant ICP27− virus. Hence the introduction of a second mutation in ICP34.5 into an ICP27− virus does not compromise the efficiency of gene delivery. This is of particular importance since unlike viruses lacking only ICP4 and/or ICP27, ICP34.5− viruses can be grown on dividing cells in culture without complementing the ICP34.5 mutation and therefore without opening up the possibility of recombination regenerating a functional ICP34.5 gene within the virus.
Such a double mutant ICP27−, ICP34.5− virus thus offers considerable potential for further development for a gene therapy vector since reversion to wild-type would require the combination of nonhomologous recombination with the complementing ICP27 gene and a second site mutation in ICP34.5 restoring a functional gene each of which will occur very rarely (less than 10 −9 for reversion of ICP27 as demonstrated in this study). Indeed, we have shown that such a double ICP27−, ICP34.5− virus not only produces far less damage to the nervous system upon injection than a virus carrying a mutation only in ICP34.5, but is also far more efficient at gene delivery than such a single mutant virus. Paradoxically therefore, it is possible to disable an ICP34.5− virus further preventing its lytic growth in all cell types and yet greatly enhance its ability to deliver specific genes.
This enhancement of gene delivery when ICP27 is inactivated within the context of ICP34.5− viruses may be related to the suggestion that the normal function of ICP34.5 is to inhibit cell death in infected neuronal cells. Thus it has been suggested 33 that when a neuronal cell is infected with an ICP34.5− virus it undergoes rapid cell death, thereby preventing the lytic replication of the virus and hence resulting in a non-neurovirulent phenotype. Although our previous demonstration 17 that ICP34.5− viruses can deliver a marker gene to neuronal cells in vivo indicates that this cannot be the case for all neuronal cells which become infected with ICP34.5− viruses, it is likely that a large proportion of the initially infected cells do die rapidly and hence do not express the marker gene. It is possible therefore that the removal of ICP27 prevents this response in such cells, thereby allowing them to survive despite the absence of ICP34.5 and therefore to express the reporter gene. Such a role for ICP27 could simply reflect the more limited gene expression which occurs in ICP27− viruses, 19 resulting in the absence of one or more other viral gene products which are required to induce the response. Alternatively, the ability of ICP27 to interfere specifically with cellular RNA metabolism by blocking processes such as RNA splicing 34 suggests the possibility that functional ICP27 itself may be involved in delivering the apoptotic signal in neuronal cells infected with HSV.
Whatever the case, it is clear that double mutant viruses with inactive ICP27 and ICP34.5 show a greatly enhanced efficiency of gene delivery and reduced neuronal damage compared with ICP34.5− viruses whilst having a comparable efficiency of gene delivery compared with a virus lacking ICP27 alone. In addition, it is of particular importance that these viruses can also deliver the ␤-galactosidase gene to the marmoset as well as the rodent brain. Thus, to our knowledge, such gene delivery to normal primate neurons in vivo has never previously been demonstrated with an HSV-based vector. This will greatly facilitate the testing of HSV vectors expressing genes of potential therapeutic importance in models of human disease. We are currently preparing ICP27−, ICP34.5− vectors expressing tyrosine hydroxylase or glial-derived neurotrophic factor in order to test these in the MPTP marmoset model of Parkinson's disease which is considered to be more relevant than unilateral rat models of nigro-striatal degeneration. 22 Although the development of efficient gene delivery systems using HSV vectors will clearly require the development of promoter systems capable of producing high efficiency long-term gene delivery, it is clear from our studies that with the appropriate combination of mutations, it is not necessary for the further disablement of an HSV-based virus for safety reasons to necessarily result in a reduced efficiency of gene delivery. Using the ICP27−, ICP34.5− virus as a basis, it may therefore be possible to develop a highly disabled virus which is safe enough for use in human gene delivery procedures whilst retaining sufficient efficiency in gene delivery to have a therapeutic benefit.
Materials and methods
Cell lines BHK 21 clone 13 cells 20 were maintained in Dulbecco's modified Eagle's medium, 10% foetal calf serum, 50 mg/ml penicillin, 50 mg/ml streptomycin (all Gibco, Paisley, UK), at 37°C with 5% CO 2 . The ICP27 complementing cell line B130/2 was made by cotransfecting the plasmid pSG130 B/S 35 with the plasmid pM5GNeo encoding a neomycin resistance gene, into BHK cells using the calcium phosphate method. 36 Drug-resistant cells were selected with 500 g/ml G418 (Geneticin sulfate; Gibco).
Plasmids
The ICP27-deletion plasmid, pZ⌬MN, was constructed as follows. pEcob, containing the HSV-1 strain 17
+ sequence between nucleotides 110095 and 131534, was digested with NotI and religated to delete nucleotides 118439 to 129778 (p⌬N). The gene encoding ICP27 was deleted by digesting p⌬N with MluI and religating (P⌬MN). This deletion, spanning nucleotides 113272 and 116869, also deleted the nonessential genes encoding UL55 and UL56. Finally, a marker gene, lacZ, driven by the Moloney murine leukaemia virus LTR promoter was introduced into the MluI site of p⌬MN as a blunt-ended fragment (pZ⌬MN18).
Recombinant viruses
Ten microgrammes of the plasmid pZ⌬MN18 were linearised by digestion with NotI and cotransfected with 10 g each of the appropriate HSV-1 genomic DNA and herring sperm carrier DNA into the B130/2 cell line using the calcium phosphate coprecipitation method. 35 Transfected monolayers were cultured until the HSV-induced cytopathic effect was present in half the monolayer. The cells were harvested and submitted to three rounds of freeze-thawing. The cell lysates were titrated on to B130/2 cells 35 and ICP27− viruses were identified by the application of the chromogen, X-gal (Melford Laboratories, Ipswich, UK), as described previously. 17 Picked blue plaques were taken through a further six rounds of plaque purification. The deletion of the ICP27 gene was confirmed by the failure of the cloned recombinants to grow on non-complementing (BHK) cells, and by Southern blot analysis. 37 In this way ICP27 was deleted from three HSV-1 backgrounds: wild type, strain 17 + ; and the ICP34.5− strain 1716. 8, 17 Preparation of dorsal root ganglion (DRG) neurons Dorsal root ganglion neurons were prepared from adult (approximately 200 g) male or female Sprague-Dawley rats essentially as described by Bevan and Winter. 38 In brief, adult rats were killed by CO 2 asphyxiation. Spinal ganglia were removed aseptically from all levels of the spinal cord. Ganglia were incubated for 3 h in 0.125% collagenase (Worthington, type IV) in F-14 medium (Imperial) with, 2 mm l-glutamine and 10 g/ml penicillin, at 37°C in a humidified incubator gassed with 3% CO 2 in air. Cells were dissociated by trituration through a flame polished Pasteur pipette. The cells were centrifuged through 2 ml of sterile 15% bovine albumin (Sigma, Poole, UK) in F-14 medium and the pellet was resuspended in F-14 with 4% Ultraser G, 2 mm l-glutamine and 10 g/ml penicillin and streptomycin (all Gibco), and 50 ng/ml nerve growth factor (Promega, Madison, WI, USA).
For culture, the cells were plated on to sterile 13-mm glass coverslips previously coated with 10 g/ml polyd-ornithine (Sigma) and 5 g/ml laminin (Gibco) and maintained at 37°C in a humidified incubator gassed with 3% CO 2 in air overnight. For replating, the cells were first plated on to 35 mm Petri dishes previously coated with poly-d-ornithine and laminin, at a density of about 1-2 × 10 4 cells per plate. When the cells were needed for study they were aspirated from the petri dish and plated on to coated 13-mm coverslips. The cells were used for recording 4-12 h after dissociation or from 2-12 h after replating. The replating step ensured that the cells were spherical and without neurites to improve the integrity of the voltage clamp.
For experiments with HSV-1 Glasgow strain 17 syn + (HSV-1) or the mutant viruses, DRG neurons were incubated with 5 p.f.u. of virus per DRG neuron in serumfree F-14 medium for 1 h and subsequently incubated in F-14 (Gibco) with 4% ultroser G, 2 mm l-glutamine and 10 g/ml penicillin and streptomycin and 50 ng/ml nerve growth factor for 24 h.
Electrophysiology
Experiments were performed on adult rat dorsal root ganglion neurons 4-12 h after plating on laminin and poly-d-ornithine coated coverslips. DRG neurons were voltage-clamped in the whole cell configuration with an Axopatch 200A amplifier (Axon Instruments, Foster City, CA, USA). Voltage-clamp potentials were generated by an IBM compatible personal computer and applied through (DMA TL-1) analogue-digital interface using PCLAMP software (Axon Instruments). Borosilicate 'patch' pipettes were pulled from 1.5 mm external diameter glass fibre-filled capillaries (Clark Electromedical, Reading, UK; GC150-F10) in a three-stage pull on a P-80 Brown-Flaming micropipette puller (Sutter Instrument, San Francisco, CA, USA). The pipettes were fire-polished and had a final resistance of 2-5 M⍀ when filled. Pipette and membrane capacitance was compensated using the circuitry on the amplifier, series resistance compensation (ෂ80%) was employed. Electrophysiological recordings were made from DRG neurons which ranged from 20 m to 50 m in diameter. The DRG neurons were clamped at a holding potential of −80 mV. Sodium currents were isolated by blocking K + channels with Cs + as the major internal cation and TEA ions externally. The Ca 2+ currents were blocked by using 10 m Ca 2+ . This concentration is sufficient to bind to high affinity binding sites within the Ca 2+ channel blocking the channels and preventing them from becoming Na + -conducting. 39 The intracellular pipette solution was composed of 130 mm CsCl, 10 mm NaCl, 10 mm EGTA, 1 mm CaCl 2 , 1 mm MgCl 2 and 10 mm Hepes, at pH 7.2. The extracellular solution was composed of 30 mm NaCl, 100 mm choline Cl, 20 mm TEA Cl, 5 mm MgCl 2 , 5 mm Hepes, 40 mm sucrose and 10 m CaCl 2 , pH 7.4. The TTXs and TTXr sodium curents were separated electrophysiologically on the basis of their different inactivation properties. The total sodium current was evoked by a 10 ms depolarising command step to +10 mV from a prepulse potential of 120 mV. TTXr sodium current was evoked from a prepulse of −50 mV with a 10 ms command potential to +10 mV. TTXs sodium current was obtained by subtraction. A family of sodium currents was generated from a holding potential of −80 mV, after a prepulse to −120 mV to remove sodium channel inactivation, using 10 ms, 5 mV step depolarisations from −50 mV to +25 mV command potentials.
All experiments were performed at room temperature, typically 22°C. All results are presented as mean ± standard error of the mean (s.e.m.).
Surgery
Male Lewis rats (6-9 weeks; Harlan Olac, UK) and three 8-9-month male marmosets (Neurodegenerative Diseases Research Centre, King's College, London, UK) were used for light microscopy (LM) and electron microscopy (EM).
The rats or marmosets were anaesthetised and placed into a stereotactic frame. A hole was then drilled through the skull and either herpes virus or diluent (tissue culture media) was injected unilaterally at a single site into the motor cortex at the following co-ordinates.
Rats Marmoset
Anterior-posterior: bregma + 9 bregma + 0.5 Lateral: bregma − 2.5 bregma + 5.5 Vertical: dura − 1.5 dura − 10.5
For LM and EM, the herpes virus stocks used were Z⌬MN:+ (1 × 10 9 p.f.u./ml), Z⌬MN:16 (1 × 10 9 p.f.u./ml), 1716 (1 × 10 9 p.f.u./ml) and diluent. A 1 l volume of viral stock or diluent was injected slowly over a period of 2 min using a fine glass micropipette (tip diameter Ͻ70 m). The glass micropipette was then left in situ for a further 10 min to allow for diffusion of the virus into the surrounding tissue before being slowly retracted and the wound closed.
Light microscopy
The time-points were 2, 5, 7, 10 and 14 days. At 2 and 5 days a minimum of three rats per time-point were used for viral and diluent injections and at 7, 10 and 14 days a minimum of two rats per time-point were used for viral injections. The rats were deeply anaesthetised and intracardially perfused with 75 ml ice cold 0.1 m PBS followed by 250 ml ice cold 4% paraformaldehyde/2 mm MgCl 2 . The brains were removed and post-fixed for 1 h before being placed into 30% sucrose in 0.1 m PBS/2 mm MgCl 2 overnight at 4°C. The brains were then sectioned at 50 m on a freezing microtome, or 75 m on a vibratome. Sections were collected in 0.1 m PBS/2 mm MgCl 2 and incubated free-floating overnight at room temperature in the X-gal histochemical stain containing 40 mg/ml 5-bromo-4 chloro-indolyl-beta-galactoside (X-gal), 100 mm potassium ferricyanide, 100 mm potassium ferrocyanide, 0.1%. Nonidet P40 0.2% sodium dexoycholate, 100 mm magnesium chloride. After incubation in X-gal, the sections were washed three times in PBS, alternate sections mounted on to glass slides, and coverslipped with aqueous mounting medium.
For each animal the number of blue cells in the motor cortex at the injection site in the X-gal-stained sections were counted with the aid of an eye piece grid and camera lucida drawings of blue cell bodies.
Electron microscopy At 3, 7, 14 and 28 days (three rats per time-point for viral and diluent injections), rats were deeply anaesthetised with Sagatal and intracardially perfused with 250 ml ice cold 2% paraformaldehyde/2% glutaraldehyde. The brains were removed and post-fixed in the same fixative overnight. The brains were sectioned horizontally at 150 m on a vibratome. Sections were collected in 0.1 m PBS and processed for electron microscopy. Briefly, the sections were post-fixed in 1% osmium tetraoxide, block stained in 2% uranyl acetate, dehydrated through ascending grades of ethanol, washed in propylene oxide and embedded in araldite resin. Semithin sections (1 m) were cut and stained with toluidine blue. A small number of sections were then selected for analysis at the electron microscope level.
